EZH2 and carcinoma: High expression of EZH2 was most commonly observed in papillary SCC (5/5, 100%) (Figure 3D) non-keratinizing SCC (30/40, 75%) (Figure 1D), basaloid SCC (2/3, 66.6%) (Figure 3B), two cases (2/3, 66.6%) of adenocarcinoma, usual type (Figure 2C) and in one case (1/1, 100%) of adenocarcinoma, gastric type (Figure 2D) while low immunoexpression of EZH2 was predominantly found in keratinizing SCC (5/6, 83.3%) (Figure 1B) and in one case (1/1, 100%) each of adenocarcinoma, clear cell type and lymphoepithelioma-like carcinoma (Table 2).